恒瑞医药披露Myosin抑制剂HRS-1893治疗梗阻性肥厚型心肌病II期研究积极结果

每日经济新闻03-31

每经AI快讯，3月31日，恒瑞医药公众号消息显示，恒瑞医药与Braveheart Bio在第75届美国心脏病学会年度科学会议上共同公布了新一代在研心肌肌球蛋白（Myosin）小分子抑制剂HRS-1893（也称BHB-1893）用于梗阻性肥厚型心肌病(oHCM)受试者的II期临床试验数据。研究显示，HRS-1893可快速、显著降低左心室流出道压差（即LVOT-G，是评估心脏梗阻程度的公认标准）。基于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2623637146?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-31 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623637146","market":"us","top_or_hot":-1,"title":"恒瑞医药披露Myosin抑制剂HRS-1893治疗梗阻性肥厚型心肌病II期研究积极结果","media":"每日经济新闻","content":"<div>\n<p>每经AI快讯，3月31日，恒瑞医药公众号消息显示，恒瑞医药与Braveheart Bio在第75届美国心脏病学会年度科学会议上共同公布了新一代在研心肌肌球蛋白（Myosin）小分子抑制剂HRS-1893（也称BHB-1893）用于梗阻性肥厚型心肌病(oHCM)受试者的II期临床试验数据。研究显示，HRS-1893可快速、显著降低左心室流出道压差（即LVOT-G，是评估心脏梗阻程度的公认标准）。基于...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603313690111336.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药披露Myosin抑制剂HRS-1893治疗梗阻性肥厚型心肌病II期研究积极结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药披露Myosin抑制剂HRS-1893治疗梗阻性肥厚型心肌病II期研究积极结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-31 10:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202603313690111336.html><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>每经AI快讯，3月31日，恒瑞医药公众号消息显示，恒瑞医药与Braveheart Bio在第75届美国心脏病学会年度科学会议上共同公布了新一代在研心肌肌球蛋白（Myosin）小分子抑制剂HRS-1893（也称BHB-1893）用于梗阻性肥厚型心肌病(oHCM)受试者的II期临床试验数据。研究显示，HRS-1893可快速、显著降低左心室流出道压差（即LVOT-G，是评估心脏梗阻程度的公认标准）。基于...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603313690111336.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828631.EUR","symbol_name":"AZ EQUITY CHINA \"A\" (EUR) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202603313690111336.html","article_id":"2623637146","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690111336.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623637146","pubTimestamp":1774923855,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"每经AI快讯，3月31日，恒瑞医药公众号消息显示，恒瑞医药与BraveheartBio在第75届美国心脏病学会年度科学会议上共同公布了新一代在研心肌肌球蛋白（Myosin）小分子抑制剂HRS-1893（也称BHB-1893）用于梗阻性肥厚型心肌病(oHCM)受试者的II期临床试验数据。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0183":"MSCI概念","BK0239":"医药制造","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK0188":"融资融券","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0028":"国家队","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1191":"制药","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0060":"抗癌","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0196":"行业龙头","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK0012":"证金概念","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","01276":"恒瑞医药","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1997245177.USD":"安联神洲A股基金","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC"},"translate_title":"Hengrui Medicine Discloses Positive Results of Phase II Study of Myosin Inhibitor HRS-1893 in Obstructive Hypertrophic Cardiomyopathy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"01276":1.5},"content_text":"每经AI快讯，3月31日，恒瑞医药公众号消息显示，恒瑞医药与Braveheart Bio在第75届美国心脏病学会年度科学会议上共同公布了新一代在研心肌肌球蛋白（Myosin）小分子抑制剂HRS-1893（也称BHB-1893）用于梗阻性肥厚型心肌病(oHCM)受试者的II期临床试验数据。研究显示，HRS-1893可快速、显著降低左心室流出道压差（即LVOT-G，是评估心脏梗阻程度的公认标准）。基于此结果，恒瑞医药已于2025年启动中国III期临床试验，Braveheart Bio也计划于2026年启动全球III期临床试验。（文章来源：每日经济新闻）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623637146","isCrawlerRequest":true}